Clinical trials have shown promising results with EZH2-specific inhibitors, including GSK126, EPZ6438, PF-06821497, Tazemetostat and CPI-1205, in treating hematological malignancies and other tumors (5, 6). The gene discussed is EZH2; the disease is hematologic disorder.